ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS

Rosen Law Firm is notifying investors in Gossamer Bio, Inc. (NASDAQ: GOSS) of a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding the Phase 3 PROSERA study design, particularly concerning placebo response controls at Latin American testing sites. Investors who purchased securities between June 16, 2025 and February 20, 2026 may be eligible for compensation. The lead plaintiff deadline is June 1, 2026.